Seminars in Hematology
Volume 45, Issue 2 , Pages 110-117 , April 2008

Non-myeloablative Radioimmunotherapy for Non-Hodgkin’s Lymphoma

  • Julia Schaefer-Cutillo
    • ,
  • Jonathan W. Friedberg

      Affiliations

    • Corresponding Author InformationAddress correspondence to Jonathan W. Friedberg, MD, Lymphoma Program, James P. Wilmot Cancer Center, University of Rochester, 601 Elmwood Ave, Box 704, Rochester, NY 14642.

References 

  1. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23:8447–8452
  2. Swenson WT, Wooldridge JE, Lynch CF, Forman-Hoffman VL, Chrischilles E, Link BK. Improved survival of follicular lymphoma patients in the United States. J Clin Oncol. 2006;23:5019–5026
  3. Friedberg JW. Unique toxicities and resistance mechanisms associated with monoclonal antibody therapy. Hematology (Am Soc Hematol Educ Program). 2005;329–334
  4. Cheson BD. Some like it hot!. J Clin Oncol. 2001;19:3908–3911
  5. Cheson BD. Radioimmunotherapy of non-Hodgkin lymphomas. Blood. 2003;101:391–388
  6. Dillman RO. Radiolabeled anti-CD20 monoclonal antibodies for the treatment of B-cell lymphoma. J Clin Oncol. 2002;20:3545–3557
  7. Friedberg JW, Fisher RI. Iodine-131 tositumomab (Bexxar): Radioimmunoconjugate therapy for indolent and transformed B-cell non-Hodgkin’s lymphoma. Expert Rev Anticancer Ther. 2004;4:18–26
  8. Witzig TE, White CA, Wiseman GA, Gordon LI, Emmanouilides C, Raubitschek A, et al. Phase I/II trial of IDEC-Y2B8 radioimmunotherapy for treatment of relapsed or refractory CD20(+) B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 1999;17:3793–3803
  9. Kaminski MS, Estes J, Zasadny KR, Francis IR, Ross CW, Tuck M, et al. Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: Updated results and long-term follow-up of the University of Michigan experience. Blood. 2000;96:1259–1266
  10. Kaminski MS, Zelenetz AD, Press OW, Saleh M, Leonard J, Fehrenbacher L, et al. Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin’s lymphomas. J Clin Oncol. 2001;19:3918–3928
  11. Witzig TE, Gordon LI, Cabanillas F, Czuczman MS, Emmanouilides C, Joyce R, et al. Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:2453–2463
  12. Fisher RI, Kaminski MS, Wahl RL, Knox SJ, Zelenetz AD, Vose JM, et al. Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin’s lymphomas. J Clin Oncol. 2005;23:7565–7573
  13. Gordon LI, Molina A, Witzig T, Emmanouilides C, Raubtischek A, Darif M, et al. Durable responses after ibritumomab tiuxetan radioimmunotherapy for CD20+ B-cell lymphoma: Long-term follow-up of a phase 1/2 study. Blood. 2004;103:4429–4431
  14. Witzig TE, White CA, Gordon LI, Wiseman GA, Emmanouilides C, Murray JL, et al. Safety of yttrium-90 ibritumomab tiuxetan radioimmunotherapy for relapsed low-grade, follicular, or transformed non-hodgkin’s lymphoma. J Clin Oncol. 2003;21:1263–1270
  15. Czuczman MS, Emmanoulides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Analysis of the incidence of treatment-related myelodysplastic syndrome and acute myelogenous leukemia in regristration and compassionate-use trials of ibritumomab tiuxetan radioimmunotherapy (RIT). J Clin Oncol. 2007;25:4285–4292
  16. Bennett JM, Kaminski MS, Leonard JP, Vose JM, Zelenetz AD, Knox SJ, et al. Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab. Blood. 2005;105:4576–4582
  17. Czuczman MS, Emmanouilides C, Darif M, Witzig TE, Gordon LI, Revell S, et al. Treatment-related myelodysplastic syndrome and acute myelogenous leukemia in patients treated with ibritumomab tiuxetan radioimmunotherapy. J Clin Oncol. 2007;25:4285–4292
  18. McLaughlin P, Estey E, Glassman A, Romaguera J, Samaniego F, Ayala A, et al. Myelodysplasia and acute myeloid leukemia following therapy for indolent lymphoma with fludarabine, mitoxantrone, and dexamethasone (FND) plus rituximab and interferon alpha. Blood. 2005;105:4573–4575
  19. Kaminski MS, Tuck M, Estes J, Kolstad A, Ross CW, Zasadny K, et al. 131I-tositumomab therapy as initial treatment for follicular lymphoma. N Engl J Med. 2005;352:441–449
  20. Witzig TE, Flinn IW, Gordon LI, Emmanouilides C, Czuczman MS, Saleh MN, et al. Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin’s lymphoma. J Clin Oncol. 2002;20:3262–3269
  21. Horning SJ, Younes A, Jain V, Kroll S, Lucas J, Podoloff D, et al. Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab. J Clin Oncol. 2005;23:712–719
  22. Kaminski MS, Radford JA, Gregory SA, Leonard JP, Knox SJ, Kroll S, et al. Re-treatment with I-131 tositumomab in patients with non-Hodgkin’s lymphoma who had previously responded to I-131 tositumomab. J Clin Oncol. 2005;23:7985–7993
  23. Justice TE, Martenson JA, Wiseman GA, Witzig TE. Safety and efficacy of external beam radiation therapy for non-Hodgkin lymphoma in patients with prior 90Y-ibritumomab tiuxetan radioimmunotherapy. Cancer. 2006;107:433–438
  24. Kaminski MS, Hamstra D, Estes J, Wahl R. The impact of FLIPI on outcome of frontline treatment with single-agent I-131 tositumomab for follicular lymphoma. J Clin Oncol. 2006;24:424S
  25. Czuczman MS, Weaver R, Alkuzweny B, Berlfein J, Grillo-Lopez AJ. Prolonged clinical and molecular remission in patients with low-grade or follicular non-Hodgkin’s lymphoma treated with rituximab plus CHOP chemotherapy: 9-year follow-up. J Clin Oncol. 2004;22:4711–4716
  26. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, LeBlanc M, et al. A phase 2 trial of CHOP chemotherapy followed by tositumomab/iodine I 131 tositumomab for previously untreated follicular non-Hodgkin lymphoma: Southwest Oncology Group protocol S9911. Blood. 2003;102:1606–1612
  27. Press OW, Unger JM, Braziel RM, Maloney DG, Miller TP, Leblanc M, et al. Phase II trial of CHOP chemotherapy followed by tositumomab/iodine I-131 tositumomab for previously untreated follicular non-Hodgkin’s lymphoma: Five-year follow-up of Southwest Oncology Group Protocol S9911. J Clin Oncol. 2006;24:4143–4149
  28. Leonard JP, Coleman M, Kostakoglu L, Chadburn A, Cesarman E, Furman RR, et al. Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma. J Clin Oncol. 2005;23:5696–5704
  29. Link B, Kaminski MS, Coleman M, Leonard JP. Phase II study of CVP followed by tositumomab and iodine-131 tositumomab (Bexxar therapeutic regimen) in patients with untreated follicular non-Hodgkin’s lymphoma. Proc Am Soc Clin Oncol. 2004;22:145;(abstr 6520)
  30. Friedberg JW, Neuberg D, Gribben JG, Mauch P, Anderson KC, Soiffer RJ, et al. Autologous bone marrow transplantation after histologic transformation of indolent B cell malignancies. Biol Blood Marrow Transplant. 1999;5:262–268
  31. Zelenetz AD, Saleh M, Vose J, Younes A, Kaminski MS. Patients with transformed low grade lymphoma attain durable responses following outpatient radioimmunotherapy with tositumomab and iodine I 131 tositumomab (Bexxar). Blood. 2002;100:357a
  32. Morschhauser F, Illidge T, Huglo D, Martinelli G, Paganelli G, Zinzani PL, et al. Efficacy and safety of yttrium-90 ibritumomab tiuxetan in patients with relapsed or refractory diffuse large B-cell lymphoma not appropriate for autologous stem-cell transplantation. Blood. 2007;110:54–58
  33. Smith MR, Chen H, Gordon L, Foran J, Kahl B, Advani R, et al. Phase II study of rituximab + CHOP followed by Y-ibritumomab tiuxetan in patients with previously untreated mantle cell lymphoma: An Eastern Cooperative Oncology Group study (E1499). J Clin Oncol. 2006;24:422S
  34. Jurczak W, Giza A, Szostek M, Hubalewska-Dydejczyk A, Sowa-Staszczak A, Knopinska-Posluszny W, et al. Zevalin radioimmunotherapy consolidation of FCM induction chemotherapy in mantle cell lymphoma patients: Results from the PLRG upon completed enrollment. Blood. 2006;108:777a
  35. Green DJ, Pagel JM, Pantelias A, Hedin N, Lin Y, Wilbur DS, et al. Pretargeted radioimmunotherapy for B-cell lymphomas. Clin Cancer Res. 2007;13:5598s–5603s
  36. Forero A, Weiden PL, Vose JM, Knox SJ, LoBuglio AF, Hankins , et al. Phase 1 trial of a novel anti-CD20 fusion protein in pretargeted radioimmunotherapy for B-cell non-Hodgkin lymphoma. Blood. 2004;104:227–236
  37. Pantelias A, Pagel JM, Hedin N, Saganic L, Wilbur S, Hamlin DK, et al. Comparative biodistributions of pretargeted radioimmunoconjugates targeting CD20, CD22, and DR molecules on human B-cell lymphomas. Blood. 2007;109:4980–4987
  38. Pagel JM, Pantelias A, Hedin N, Wilbur S, Saganic L, Lin Y, et al. Evaluation of CD20, CD22, and HLA-DR targeting for radioimmunotherapy of B-cell lymphomas. Cancer Res. 2007;67:5921–5928
  39. Linden O, Hindorf C, Cavallin-Stahl E, Wegener WA, Goldenberg DM, Horne H, et al. Dose-fractionated radioimmunotherapy in non-Hodgkin’s lymphoma using DOTA-conjugated, 90Y-radiolabeled, humanized anti-CD22 monoclonal antibody, epratuzumab. Clin Cancer Res. 2005;11:5215–5222
  40. DeNardo GL, DeNardo SJ, Goldstein DS, Kroger LA, Lamborn KR, Levy NB, et al. Maximum-tolerated dose, toxicity, and efficacy of (131)I-Lym-1 antibody for fractionated radioimmunotherapy of non-Hodgkin’s lymphoma. J Clin Oncol. 1998;16:3246–3256
  41. Cooney-Qualter E, Krailo M, Angiolillo A, Fawwaz RA, Wiseman G, Harrison L, et al. A phase I study of 90yttrium-ibritumomab-tiuxetan in children and adolescents with relapsed/refractory CD20-positive non Hodgkin’s lymphoma: A Children’s Oncology Group study. Clin Cancer Res. 2007;13:5652s–5660s

 J.W.F. is supported in part by a career development award from the National Cancer Institute (CA-102216).

PII: S0037-1963(08)00010-3

doi: 10.1053/j.seminhematol.2008.02.009

Seminars in Hematology
Volume 45, Issue 2 , Pages 110-117 , April 2008

Article Tools

* Image Usage & Resolution